Skip to content

Transversus Abdominis Plane (TAP) Block Versus Intrathecal Morphine for Caesarean Section - Randomised Controlled Trial

Transversus Abdominis Plane (TAP) Block Versus Intrathecal Morphine for Caesarean Section - Randomised Controlled Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01931215
Acronym
MOTAP
Enrollment
180
Registered
2013-08-29
Start date
2013-09-30
Completion date
2017-08-28
Last updated
2017-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

Analgesia after cesarean section is still not satisfactory for many women. Even if pain reduction is sufficient with the technique of intrathecal morphine injection, side effects such as nausea and pruritus are common. Since several years, an alternative technique has been studied, the transversus abdominis plane (TAP)-block. Here a local anesthetic is injected in the abdominal wall muscles, and this has been shown to give a similar analgesic effect compared to intrathecal morphine, with potentially less side effects. With this study, we want to evaluate if the TAP-block yields indeed less side effects when compared with intrathecal morphine. The study will be a prospective study with the patients randomized to either a group with intrathecal morphine or a group with TAP-block.

Interventions

in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added

OTHERTAP-block with ropivacaine and clonidine

Sponsors

Domitille Dereu
CollaboratorUNKNOWN
Benno Rehberg-Klug
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

pharmacy providing identical sets of study drugs and placebo, computerized random sequence generation, sequence held by the pharmacy until study completion

Intervention model description

treatment versus placebo

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Subjects must satisfy all of the following criteria to be enrolled into the study: * American Society of Anesthesiology (ASA) physical status less than 3 Able to read and understand the information sheet and to sign and date the consent form * Scheduled for elective C-section planned with spinal anaesthesia * Age\>18

Exclusion criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study: * Complicated pregnancy defined as having preeclampsia or placenta accreta, increta and percreta. * Drug addiction. * Contraindication to spinal anaesthesia (history of clotting disorders, septicemia, local infection at the injection site, spinal malformation, elevated intracranial pressure) * Contraindication to TAP block (skin infection, abdominal wall muscle defect such as hernia and previous abdominal wall mesh). * BMI\>40 kg/m2 * Weight less than 50 kg the day of the C-section. * Height less than 150 cm or more than 175 cm. * Allergy/contraindication to any medication used in the study. * Previous median abdominal incision. Necessity to perform the C-section urgently before the scheduled date (with less than 24h preparation time).

Design outcomes

Primary

MeasureTime frameDescription
cumulative incidence of nausea and/or vomiting at 24 hours24 hoursData for this endpoint will be gathered at 6h and 24h postoperatively from nurses' records in the recovery room (at 6h) and on the ward (at 24h), and counterchecked by asking the patient

Secondary

MeasureTime frameDescription
Cumulative incidence of treated nausea and vomiting at 24h24h(inquired directly from the patient at 6 and 24h).
Cumulative incidence of sedation at 6 and 24h.24hSedation defined as an observer's assessment of alertness and sedation (OAAS) score lower than 4
Cumulative incidence of arterial hypotension24hdefined as a systolic blood pressure of less than 100 mmHg for longer than 5 minutes (from nurse records at 6 and 24h)
Cumulative incidence of bradycardia24hdefined as a heart rate of less than 50/min for longer than 5 minutes (from nurse records at 6 and 24h)
Cumulative incidence of respiratory depression24hdefined as a respiratory frequency of less than 8/min for longer than 5 minutes (from nurse records at 6 and 24h
Cumulative incidence of pruritus at 24h24 hinquired directly from the patient at 6 and 24h
Time until first PCA request24h(recorded in the memory of the PCA pump
Pain score at rest at 6, 24 and 48 hours postoperatively48husing the NRS scale (0-10)
Pain score on movement48hat 24 and 48 hours postoperatively (using the numerical rating scale (NRS 0-10)).
Maternal satisfaction at 24 and 48 hours postoperatively48hmeasured on a numeric rating scale (at 6h) and with the questionnaire quality of recovery (QoR40) at 24 and 48h
persistent pain at 3 and 6 months postoperatively6 monthsPain at rest, 0-10 pain scale; Pain on movement, 0-10 pain scale; Yes/no for scar pain;Yes/no for analgesic use
Cumulative morphine consumption at 24 hours24h(recorded in the memory of the patient controlled analgesia (PCA) pump).

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026